Talk Bio

BioNTech and Bristol Myers Squibb (BMS) presented the first global data for their PD-L1xVEGF bispecific antibody (BNT327, also called pumitamig) in small cell lung cancer at the 2025 World Conference on Lung Cancer 1 . In the global phase 2 trial, pumitamig combined with chemotherapy achieved a confirmed overall response rate (ORR) of 76.3% among 38 evaluable untreated extensive-stage small cell lung cancer (ES-SCLC) patients 1 3 . All patients in the study achieved disease control, with a median duration of response of five months, and response rates were 85% at 20 mg/kg and 66.7% at 30 mg/kg 1 . The global phase 3 dose has been selected and is being used in an ongoing phase 3 trial of pumitamig plus chemotherapy for extensive-stage SCLC. Data readout from the phase 3 trial is expected by 2028 3 . BNT327 targets two key pathways: PD-L1 (to restore T-cell mediated anti-tumor immunity) and VEGF-A (to inhibit tumor growth and angiogenesis), aiming for a synergistic effect 4 5 ....